Vaxart oral coronavirus vaccine begins phase 1 trial

16 October, 2020

Vaxart, a San Francisco-based biotech company, has announced that the first volunteer in their Phase 1 trial of oral coronavirus vaccine, VXA-CoV2-1, has been given the vaccine. VXA-CoV2-1 is a recombinant adenoviral mucosal vaccine.

Pre-clinical data showed that the vaccine induces both a robust systemic immune response (humoral and cellular) and a strong mucosal immune response, specifically in the lungs.

The Phase 1 trial will enrol 48 healthy adult volunteers aged 18 to 54 years. Participants will receive the low or high dose of the VXA-CoV2-1 oral tablet at days 1 and 29. Safety, reactogenicity and immunogenicity assessments will be performed at set times during the trial.

LATEST NEWS

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Webinars

Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars